Abstract:Aims: To present the clinical features of two rare cases with hereditary renal glycosuria and diabetes, and summarize the previously reported SLC5A2 mutations and the related phenotypes. Methods: The two patients were followed up for 7 and 3 years respectively, and detailed clinical characteristics were collected. SLC5A2 and HNF1A gene were sequenced. We used flash glucose monitoring system to record the variation of glucose with and without SGLT2 inhibitor treatment. Then we retrieved all the literature from Pubmed and analyzed SLC5A2 gene mutations and the phenotypes. Results: During regular long-time follow up, the two patients both had frequent un-proportional renal glycosuria in the morning even when their fasting serum glucose was only slightly increased above the normal range. A novel rare mutation V359G and a pathogenic rare mutation ivs7+5G>A in SLC5A2 gene were found in Case 1 and Case 2 respectively. In Case 1, the 24h glycosuria was 2.2g/d, and increased to 103g/day after dapaglifozin treatment. The average glucose (6.33±1.56 vs. 6.28±1.74mmol/L, P=0.663), and Time in Range (TIR) (95% vs. 93%) were not significantly different in metformin and dapaglifozin treatment respectively. In Case 2, the 24h glycosuria was 121.4g/d and increased to 185.8g/day after dapaglifozin add-on treatment, with a further reduction of average glucose (9.11±2.63 vs. 7.54±2.39mmol/L, P<0.001), and better TIR 70% vs. 84%. We reviewed 139 cases with hereditary renal glycosuria and SLC5A2 gene mutation. The quantity of urine glucose was highest in patients with homozygous mutation (64.0(36.6-89.6)g/24h) compared with compound heterozygous (25.9(14.4-41.2)g/24h) and heterozygous(3.45(1.41-7.50)g/24h) (P<0.001). Conclusions: Genetic renal glycosuria could not be translated into protecting individuals completely from developing diabetes. The response of these patients suggested that even in diabetic patients with decreased renal glucose threshold, SGLT2 inhibitor could also be effective. Disclosure Q. Ren: None. S. Gong: None. X. Han: None. L. Ji: None. Funding National Key Research and Development Program of China (2016YFC1304901); Beijing Municipal Commission of Science and Technology (Z141100007414002, D131100005313008)

Novel Slc5a2 Variants Contribute to Renal Glucosuria in Chinese Families: Abnormal Expression and Dysfunction of Variant Slc5a2

SLC5A2 mutations, including two novel mutations, responsible for renal glucosuria in Chinese families.

Novel Slc5a2 Mutation Contributes to Familial Renal Glucosuria: Abnormal Expression in Renal Tissues

Abnormal Expression and Dysfunction of Novel SGLT2 Mutations Identified in Familial Renal Glucosuria Patients.

A novel compound heterozygous mutation in SLC5A2 contributes to familial renal glucosuria in a Chinese family, and a review of the relevant literature.

Genetic and clinical characterization of familial renal glucosuria

Decreased expression and function of sodium-glucose co-transporter 2 from a novel C-terminal mutation: a case report

A novel heterozygous likely pathogenic SLC5A2 variant in a diabetic patient with glucosuria and aminoaciduria

774-P: Hereditary Renal Glycosuria, Diabetes, and Responses to SGLT2 Inhibitor

Clinical and Genetic Features of Patients With Type 2 Diabetes and Renal Glycosuria.

A Novel Compound Heterozygous Variant of the SLC12A3 Gene in Gitelman Syndrome Pedigree

The clinical manifestation and gene mutation of primary renal glucosuria in a child

Familial renal glycosuria identified in an Indian family

Association between SLC2A9 transporter gene variants and uric acid phenotypes in African American and white families

Glucose transporter‐1 deficiency syndrome with extreme phenotypic variability in a five‐generation family carrying a novel SLC2A1 variant

Novel Variants in CRB2 Targeting the Malfunction of Slit Diaphragm Related to Focal Segmental Glomerulosclerosis

Three novel SLC37A4 variants in glycogen storage disease type 1b and a literature review

Novel pathogenic variants of SLC38A8 gene and literature review

Novel SLC12A3 mutations in Chinese patients with Gitelman's syndrome.

Functional evaluation of a novel GLA causative mutation in Fabry disease.

SLC12A3 Variation and Renal Function in Chinese Patients With Hypertension